Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: A multicenter, randomized, double-masked comparative study

Japanese Journal of Ophthalmology

Volumn 52, Issue 4, 2008, Pages 255-264

  Araie, Makoto ^a   Shirato, Shiroaki ^b,k,r   Yamazaki, Yoshio ^c,h   Kitazawa, Yoshiaki ^d   Ohashi, Yasuo ^e   Hara, Takeshi ^f   Hashimoto, Takako ^f   Tsuru, Tadahiko ^f   Kojima, Takayoshi ^g   Tomidokoro, Atsuo ^g,p   Nakajima, Fumiko ^g   Obata, Ryo ^g   Nakagami, Takako ^h   Hayamizu, Fukuko ^h   Yamagami, Junkichi ⁱ   Suzuki, Junko ⁱ   Kishimoto, Shuichi ⁱ   Oshima, Yuri ⁱ   Nakayama, Kei ⁱ   Otake, Yuichiro ^j   Kimura, Itaru ^j   Tanino, Tomihiko ^j   Haneda, Mai ^k   Kimura, Tairo ^l   Kawabata, Kiho ^l   Yasuda, Noriko ^m   Nakamoto, Kenji ^m   Matsumoto, Shun ⁿ   Yoshimoto, Miwako ⁿ   Suzumura, Hirotaka ^o,t   Tomita, Goji ^p   Suzuki, Yasuyuki ^p   Kunimatsu, Shiho ^p   Nakano, Tadashi ^q   Maruyama, Katsuhiko ^r   Inoue, Toyoko ^s   Kouzaki, Ai ^s   Inoue, Yoichi ^s   Yoshikawa, Keiji ^u   Miyata, Hiroshi ^v   Shirakashi, Motohiro ^w   Kashiwagi, Kenji ^x   Iwase, Aiko ^y   Shono, Yuko ^y   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b Yotsuya Shirato Eye Clinic   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Akasaka Kitazawa Eye Clinic   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g SAITAMA RED CROSS HOSPITAL   (Japan)

^h NIHON UNIVERSITY   (Japan)

ⁱ JR Tokyo General Hospital   (Japan)

^j KEIO UNIVERSITY HOSPITAL   (Japan)

^k TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^l Ueno Eye Clinic   (Japan)

^m TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

ⁿ TOKYO TEISHIN HOSPITAL   (Japan)

^o Nakano General Hospital   (Japan)

^p UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^q JIKEI UNIVERSITY HOSPITAL   (Japan)

^r TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^s Olympia Eye Hospital   (Japan)

^t Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^u Yoshikawa Eye Clinic   (Japan)

^v YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^w NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^x YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^y Tajimi Municipal Hospital   (Japan)

more..

Author keywords

Clinical trial; Glaucoma; Nipradilol; Timolol; Visual field

Indexed keywords

NIPRADILOL; TIMOLOL;

ADULT; ANALYZER; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL FIELD;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PERIMETRY; PROPANOLAMINES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL FIELDS;

EID: 51349136225     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-008-0540-z     Document Type: Article

References (42)

1. Collaborative Normal-Tension Glaucoma Study Group. 1998 Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure Am J Ophthalmol 126 487 497
2. Collaborative Normal-Tension Glaucoma Study Group. 1998 The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am J Ophthalmol 126 498 505
3. The AGIS Investigators. 2000 The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol 130 429 440
4. P.R. Lichter D.C. Musch B.W. Gillespie CIGTS Study Group 2001 Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 108 1943 1953
5. A. Heijl M.C. Leske B. Bengtsson The Early Manifest Glaucoma Trial Group 2002 Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial Arch Ophthalmol 120 1268 1279
6. D.R. Anderson 1989 The damage caused by pressure. XLVI Edward Jackson Memorial Lecture Am J Ophthalmol 108 485 495
7. R.D. Fechtner R.N. Weinreb 1994 Mechanisms of optic nerve damage in primary open-angle glaucoma Surv Ophthalmol 39 23 42
8. M. Araie I. Azuma Y. Kitazawa 2003 Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients Jpn J Ophthalmol 47 199 207
9. 2+- antagonist on visual field in low-tension glaucoma Graefes Arch Clin Exp Ophthalmol 227 408 412
10. A. Sawada Y. Kitazawa T. Yamamoto I. Okabe K. Ichien 1996 Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma Ophthalmology 103 283 288
11. N. Koseki M. Araie J. Yamagami S. Shirato S. Yamamoto 1999 Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure J Glaucoma 8 117 123
12. Y. Uchida M. Nakamura S. Shimizu M. Fujii 1983 Vasoactive and β-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3- isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent Arch Int Pharmacodyn 262 132 149
13. A. Ohira Y. Wada M. Fujii 1985 Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues Arch Int Pharmacodyn 278 61 71
14. M. Kanno M. Araie K. Tomita K. Sawanobori 1998 Effects of topical nipradilol, a β-blocking agent with α-blocking and nitroglycerinlike activities, on aqueous humor dynamics and fundus circulation Invest Ophthalmol Vis Sci 39 736 743
15. M. Kanno M. Araie H. Koibuchi K. Masuda 2000 Effects of topical nipradilol, a β blocking agent with α blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans Br J Ophthalmol 84 293 299
16. M. Kanno M. Araie K. Masuda 2006 Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension Arzneimittelforschung 56 729 734
17. M. Kanno M. Araie K. Masuda 2006 Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension Arzneimittelforschung 56 820 825
18. K. Mizuno T. Koide M. Yoshimura M. Araie 2001 Neuroprotective effect and intraocular penetration of nipradilol, a β-blocker with nitric oxide donative action Invest Ophthalmol Vis Sci 42 688 694
19. K. Kashiwagi Y. Iizuka S. Tsukahara 2002 Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells J Glaucoma 11 231 238
20. K. Mizuno T. Koide N. Saito 2002 Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys Invest Ophthalmol Vis Sci 43 3243 3250
21. J.P. Matts J.M. Lachin 1988 Properties of permuted-block randomization in clinical trials Control Clin Trials 9 327 344
22. M.O. Gordon J.A. Beiser J.D. Brandt 2002 The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma Arch Ophthalmol 120 714 720
23. P.C. O'Brien 1984 Procedures for comparing samples with multiple endpoints Biometrics 40 1079 1087
24. Y. Suzuki Y. Kitazawa M. Araie 2001 Mathematical and optimal clustering of test points of the central 30-degree visual field of glaucoma J Glaucoma 10 121 128
25. C. Mayama M. Araie Y. Suzuki 2004 Statistical evaluation of the diagnostic accuracy of methods used to determine the progression of visual field defects in glaucoma Ophthalmology 111 2117 2125
26. T. Shigeeda A. Tomidokoro M. Araie N. Koseki S. Yamamoto 2002 Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma Ophthalmology 109 766 770
27. T. Nakazawa H. Tomita K. Yamaguchi 2002 Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells Curr Eye Res 24 114 122
28. M. Taniai E. Sato A. Mizota E. Adachi-Usami 2002 Protective action of nipradilol against ischemia-induced retinal damage in rats Ophthalmic Res 34 331 337
29. H. Tomita T. Nakazawa E. Sugano T. Abe M. Tamai 2002 Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway Eur J Pharmacol 452 263 268
30. A. Ando Y. Yamazaki S. Kaneko 2005 Cytoprotection by nipradilol, an anti-glaucomatous agent, via down-regulation of apoptosis related gene expression and activation of NF-κB Exp Eye Res 80 501 507
31. N.N. Osborne C. Cazevieille A.L. Carvalho A.K. Larsen L. DeSantis 1997 In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent Brain Res 751 113 123
32. R.L. Gross S.H. Hensley F. Gao S.M. Wu 1999 Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of β-blockers Surv Ophthalmol 43 Suppl1 S162 170
33. A.A. Acheampong M. Shackleton B. John J. Burke L. Wheeler D. Tang-Liu 2002 Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes Drug Metab Dispos 30 421 429
34. 1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries Invest Ophthalmol Vis Sci 45 4041 4048
35. D.R. Anderson S.M. Drance M. Schulzer Collaborative Normal-Tension Glaucoma Study Group 2001 Natural history of normal-tension glaucoma Ophthalmology 108 247 253
36. G. Tomita M. Araie Y. Kitazawa S. Tsukahara 2004 A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients Eye 18 984 989
37. W. Goto T. Ota N. Morikawa 2002 Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina Brain Res 958 10 19
38. Y.N. Chen H. Yamada W. Mao S. Matsuyama M. Aihara M. Araie 2007 Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of β-adrenergic antagonists Brain Res 1148 28 37
39. E.B. Werner S.M. Drance 1977 Early visual field disturbances in glaucoma Arch Ophthalmol 95 1173 1175
40. W.M. Hart Jr B. Becker 1982 The onset and evolution of glaucomatous visual field defects Ophthalmology 89 268 279
41. Y. Yamada R. Takayanagi K. Tsuchiya 2001 Assessment of systemic adverse reactions induced by ophthalmic β-adrenergic receptor antagonists J Ocul Pharmacol Ther 17 235 248
42. Y. Yamada R. Takayanagi T. Ozeki H. Yokoyama T. Iga M. Araie 2006 Predicting systemic adverse effects associated with nipradilol ophthalmic solution based on β-receptor occupancy Atarashii Ganka (J Eye) 23 87 94